Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Are at least age 18 at screening (Visit 1)~2. Have a diagnosis of primary aHUS, persistent HSCT-associated TMA or TTP~3. No clinically apparent alternative explanation for thrombocytopenia and anemia~Exclusion Criteria:~1. Had eculizumab therapy within three months prior to screening~2. Have STEC-HUS~3. Have a positive direct Coombs test~4. Have an active systemic bacterial or fungal infection requiring antimicrobial therapy (prophylactic antimicrobial therapy administered as standard of care is allowed)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OMS721 low dose (Type: EXPERIMENTAL): Administration of OMS721 at a low dose
- OMS721 medium dose (Type: EXPERIMENTAL): Administration of OMS721 at a medium dose
- OMS721 high dose (Type: EXPERIMENTAL): Administration of OMS721 at a high dose

Based on this trial design, predict the completion outcome and termination type (if applicable).